In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating Miebo for the treatment of dry eye disease.
Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) demonstrated statistically significant improvements in both signs and symptoms in all patients analyzed. Sheppard also explained why the safety profile of Miebo is “unprecedented.”
“This data tells us that [perfluorohexyloctane] is a versatile, vehicle-only medication. It has a small drop size of 11 µL, it is